Impactos do tratamento com liraglutida na progressão da doença renal crônica em pacientes com diabetes mellitus tipo 2 / Impacts of treatment with liraglutide on the progression of chronic kidney disease in patients with type 2 diabetes mellitus

Vitor Augusto Lima do Vale, Gustavo Mariano Rodrigues Santos, Amália Assis de Freitas, Caio Cesar Rodrigues Leite Araruna, Emanuel Henrique Barros Dornelas, Gabriel Salgado Fernandes de Miranda, Gabriela Basso Pedro Cavalcante Costa, Júlia Argolo Assis, Liana Tarnopolsky, Melina Bequer de Sousa

Abstract


INTRODUÇÃO: A doença renal diabética é uma importante complicação decorrente da diabetes mellitus tipo 2. O estudo visa analisar o impacto da utilização da liraglutida, um fármaco agonista de GLP-1, no controle desse agravo. METODOLOGIA: Foi realizada uma revisão narrativa baseada em artigos encontrados entre os anos 2016 e 2020, nas bases de dados LILACS e PubMed, por meio de consulta ao DeCs, através dos descritores: GLP-1, liraglutide, diabetes mellitus e kidney chronic disease. RESULTADOS: Foram selecionadas 9 publicações para serem utilizadas como referencial para este artigo. DISCUSSÃO: Estudos estão sendo realizados a fim de identificar medicamentos que controlam a glicemia e sejam eficazes na preservação da função renal, assim evidenciou-se a Liraglutida. O fármaco apresentou bons resultados sobre o controle glicêmico, mostrando-se mais eficaz em relação a outros medicamentos. Além disso, foram evidenciados resultados positivos sobre o controle da obesidade e da pressão arterial, sendo esses fatores contribuintes para diminuir a progressão da doença renal diabética. Importante ressaltar também a atuação da liraglutida no sistema renal, reduzindo o declínio da taxa de filtração glomerular e os valores de albuminúria. CONCLUSÃO: A liraglutida se mostrou eficiente na redução da progressão da doença renal crônica em pacientes diabéticos tipo 2.


Keywords


Liraglutida, Insuficiência Renal Crônica, Diabetes Mellitus, Incretinas, Albuminúria.

References


AGUIAR, L. K.; et al. Fatores associados à doença renal crônica: inquérito epidemiológico da Pesquisa Nacional de Saúde. Revista Brasileira de Epidemiologia. Rio de Janeiro, v. 23, 2020.

AMERICAN DIABETES ASSOCIATION. 9. Abordagens farmacológicas do tratamento glicêmico: Standards of Medical Care in Diabetes - 2019. Diabetes Care 2019; 42 (Suppl. 1): S90 – S102. 2019

ANVISA. Victoza (liraglutida): nova indicação. novo nordisk farmacêutico do brasil LTDA, 2019

CARVALHO, D. et al. Agonistas dos Receptores do GLP-1 no Tratamento da Diabetes Tipo 2. Revista Portuguesa de Diabetes, v. 11, n. 4, p. 154-166, 2016.

COHEN, R. V.; et al. Effect of Gastric Bypass vs Best Medical Treatment on Early-Stage Chronic Kidney Disease in Patients With Type 2 Diabetes and Obesity: A Randomized Clinical Trial. JAMA Surgery, p. e01-e11, 2020.

DAVIES, M. J.; et al. Efficacy and safety of liraglutide versus placebo as add-on to glucose-lowering therapy in patients with type 2 diabetes and moderate renal impairment (LIRA-RENAL): a randomized clinical trial. Diabetes care, v. 39, n. 2, p. 222-230, 2016.

DIRETRIZES DA SOCIEDADE BRASILEIRA DE DIABETES,2019-2020. Clanad: editora científica. 2019

DRUCKER, D. J. Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1. Biology, Medicine. [S.l], v. 27, n. 4, pp.740-756. 2018.

FERREIRA, A.; et al. Treatment options for type 2 diabetes mellitus in patients with chronic kidney disease-old and new drugs. Portuguese Journal of Nephrology & Hypertension, v. 33, n. 2, p. 98-106, 2019.

GELONEZE, B.; et al. Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs) in the Brain-Adipocyte Axis. Drugs vol. 77,5 : 493-503. 23 fev. 2017.

GÓRRIZ, J. L.; et al. GLP-1 Receptor Agonists and Diabetic Kidney Disease: A Call of Attention to Nephrologists. Journal of Clinical Medicine, v. 9, n. 4, p. 947, 2020.

HINNEN, D. Glucagon-like peptide 1 receptor agonists for type 2 diabetes. Diabetes Spectrum, v. 30, n. 3, p. 202-210, 2017.

HTIKE, Z. Z. et al. Efficacy and safety of glucagon?like peptide?1 receptor agonists in type 2 diabetes: a systematic review and mixed?treatment comparison analysis. Diabetes, Obesity and Metabolism, v. 19, n. 4, p. 524-536, 2017.

IOANNIDIS, I. Diabetes treatment in patients with renal disease: Is the landscape clear enough?. World journal of diabetes, v. 5, n. 5, p. 651, 2014.

KAWANAMI, D.; TAKASHI, Y. GLP-1 Receptor Agonists in Diabetic Kidney Disease: From Clinical Outcomes to Mechanisms. Frontiers in Pharmacology, v. 11, p. 967, 2020.

LUCAS, M. D. G.; et al. Liraglutide preserves renal function in overweight diabetic patients with stage 3 chronic kidney disease. European Journal Of Internal Medicine, [S.L.], v. 44, p. 28-29, out. 2017.

MANN, J. F .E.; et al. Safety of Liraglutide in Type 2 Diabetes and Chronic Kidney Disease. Clinical Journal of the American Society of Nephrology, v. 15, n. 4, p. 465-473, 2020.

MANN, J. F. E.; et al. Liraglutide and renal outcomes in type 2 diabetes. New England Journal of Medicine, v. 377, n. 9, p. 839-848, 2017.

MOLLAOGLU, M. Quality of Life in Patients with Chronic Renal Failure and Some Affecting Factors. Archives Of Renal Diseases And Management, [S.L.], p. 012-019, 29 maio 2017.

NAVARRO-SOLANO, J.; CHEN-KU, C.. Actualización del efecto de los antihiperglicemiantes en la función renal en diabetes mellitus tipo 2. Acta méd. costarric, San José , v. 60, n. 2, p. 6-14, June 2018 .

OSONOI, T.; et al. Liraglutide Improves Estimated Glomerular Filtration Rate Slopes in Patients with Chronic Kidney Disease and Type 2 Diabetes: a 7-year retrospective analysis. Diabetes Technology & Therapeutics, [S.L.], p. 1-4, 12 jun. 2020.

PI-SUNYER, X.; et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. New England Journal of Medicine, v. 373, n. 1, p. 11-22, 2015.

RONDINELLI, Maurizio; et al. Use of Liraglutide in the Real World and Impact at 36 Months on Metabolic Control, Weight, Lipid Profile, Blood Pressure, Heart Rate, and Renal Function. Clinical Therapeutics, [S.L.], v. 39, n. 1, p. 159-169, jan. 2017.

SAEEDI, P.; et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th edition: Diabetes Research and clinical Practice v 157 , novembro de 2019.

SCHOLTEN, B. J. V.; et al. The effect of liraglutide on renal function: a randomized clinical trial. Diabetes, Obesity And Metabolism, [S.L.], v. 19, n. 2, p. 239-247, 21 nov. 2016.

SKOV, J. et al. Short?term effects of liraglutide on kidney function and vasoactive hormones in type 2 diabetes: a randomized clinical trial. Diabetes, Obesity and Metabolism, v. 18, n. 6, p. 581-589, 2016.

SLOAN, L. A. Review of glucagon?like peptide?1 receptor agonists for the treatment of type 2 diabetes mellitus in patients with chronic kidney disease and their renal effects. Journal of diabetes, v. 11, n. 12, p. 938-948, 2019.

TONNEIJCK, L.; et al. Renal effects of DPP-4 inhibitor sitagliptin or GLP-1 receptor agonist liraglutide in overweight patients with type 2 diabetes: a 12-week, randomized, double-blind, placebo-controlled trial. Diabetes Care, v. 39, n. 11, p. 2042-2050, 2016.

TOYAMA, T.; et al. Insulin and glucose-lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database Syst Rev. 2018;9(9):CD011798. Published 2018 Sep 24.

VILLARINO, A. V.; et al. Mechanisms of Jak/STAT Signaling in Immunity and Disease. The Journal Of Immunology, [S.L.], v. 194, n. 1, p. 21-27, 2015.

ZAVATTARO, M.; et al. One-year treatment with liraglutide improved renal function in patients with type 2 diabetes: a pilot prospective study. Endocrine, [S.L.], v. 50, n. 3, p. 620-626, 9 jan. 2015.

ZITMAN?GAL, T.; et al. Effect of liraglutide on the Janus kinase/signal transducer and transcription activator (JAK/STAT) pathway in diabetic kidney disease in db / db mice and in cultured endothelial cells. Journal Of Diabetes, [S.L.], v. 11, n. 8, p. 656-664, 28 fev. 2019.




DOI: https://doi.org/10.34119/bjhrv3n4-362

Refbacks

  • There are currently no refbacks.